Table 1.

Baseline patient characteristics

Genotype
Mutant BRAFWild-typea
All (n = 36)V600E (n = 18)Non-V600E (n = 18)(n = 257)
CharacteristicN (%)N (%)N (%)N (%)
Median age, y62636162
 Range(41–94)(50–94)(41–78)(26–87)
Gender
 Male17 (47)8 (44)9 (50)128 (50)
 Female19 (53)10 (56)9 (50)129 (50)
Race
 White, non-Hispanic34 (94)16 (88)18 (100)222 (86)
 Asian0 (0)0 (0)0 (0)15 (6)
 Black1 (3)1 (6)0 (0)16 (6)
 White, Hispanic0 (0)0 (0)0 (0)3 (1)
 Unknown1 (3)1 (6)0 (0)1 (<1)
Smoking historyb
 Never-smoker7 (19)5 (28)2 (11)56 (22)
 ≤10 pack-years4 (11)1 (6)3 (17)29 (11)
 >10 pack-years25 (69)12 (67)13 (72)171 (67)
Histology
 Adenocarcinoma34 (94)17 (94)17 (94)222 (87)
 Adenosquamous0 (0)0 (0)0 (0)3 (1)
 Squamous0 (0)0 (0)0 (0)6 (2)
 LCNEC0 (0)0 (0)0 (0)5 (2)
 NSCLC NOS2 (6)1 (6)1 (6)21 (8)
Stagec
 I4 (11)2 (11)2 (11)34 (13)
 II1 (3)1 (6)0 (0)17 (7)
 III6 (17)2 (11)4 (22)66 (26)
 IV25 (69)13 (72)12 (67)140 (54)

Abbreviations: LCNEC, large cell neuroendocrine carcinoma; NOS, not otherwise specified.

  • aWild-type at all predefined exons of BRAF, EGFR, KRAS, and no ALK rearrangement.

  • bData not available for 1 patient in the wild-type cohort.

  • cStage at initial NSCLC diagnosis, American Joint Committee on Cancer (AJCC) staging system 7th edition.